Precis: Dose-dense chemotherapy appears to improve the prognosis of patients with drugresistant disease, however, the mechanistic basis for this effect has been undefined.
Introduction
Epithelial ovarian carcinoma (EOC) has the highest mortality rate among gynecological malignancies since it is typically asymptomatic and undiagnosed until the disease has progressed to advanced stages. Typical treatment for ovarian cancer is cytoreductive surgery when possible, followed by adjuvant chemotherapy. The introduction of modern platinum-based combination chemotherapy with paclitaxel has improved the 5-year survival rate of patients with advanced EOC; however, long-term prognosis remains unfavorable. Disease relapse, acquired drugresistance, and short duration of progression-free survival are common and therefore, have motivated the search for better treatments.
Few phase III trials that investigated modifications to standard chemotherapy have produced encouraging results (1) (2) (3) . Thus far, the condensed treatment interval method first advocated by van der Burg and colleagues, now known as dose dense (DD) chemotherapy, is considered to be one of the most promising treatment strategy (4) . Theoretically, DD regimen deprives cancer cells the opportunity to proliferate and impedes tumor progression via the antiangiogenic effects of paclitaxel (5) . However, DD regimen is not without complications since it may be overly hematologically toxic and consequently force the premature cessation of treatment (5) . To offset toxicity and enhance treatment tolerability, DD regimen may be modified to use low drug dosages (6, 7) .
The clinical trials of dose dense platinum-based combination chemotherapy have reported promising outcomes for patients with advanced EOC. One randomized phase I/II trial investigating the efficacy of cisplatin and paclitaxel found response rates of 94% for chemotherapy-naïve patients and 84% for patients with recurrent disease (8) . Another phase II study of weekly cisplatin with an etoposide reported similar results (4) .
The Japanese Gynecologic Oncology Group (JGOG 3016) conducted a randomized phase III trial comparison of MTD treatment versus DD treatment of advanced ovarian cancer. The "partial" dose dense protocol, consisting of six 21-day cycles of intravenous carboplatin (AUC 6) on day 1 in addition to paclitaxel (80mg/m 2 ) on days 1, 8, and 15, significantly lengthened the median progression-free survival of patients (5) . Notably, evidence suggests that dose dense platinum-based combination therapy is a worthwhile option that can be safely extended, even for heavily-treated patients with notoriously difficult drug-resistant disease (9) . In theory, patients
with platinum-resistant disease should be unresponsive to any platinum-based treatment;
however this supposition is contradicted by evidence. We speculate that platinum agent and paclitaxel given in a dose dense schedule at low dosages lead to the utilization of an immunemediated tumor-killing pathway that is compromised when the drugs are given in the MTD regimen.
This study compares the efficacy and toxicity of platinum-based combination therapy administered in the DD and MTD regimen. We then determined if antitumor effects involved the immune system. Since the experimental results from mouse models of platinum-resistant tumors suggested the DD regimen is superior and has immune-mediated efficacy, the treatment was examined in 14 patients with relapse of EOC. 
Materials and Methods
Mouse and cell lines C57BL/6, (C57BL/6×C3/He) F1 mice and athymic nude mice were purchased from BioLASCO, Taiwan. All animals were maintained under specific pathogen-free conditions. All procedures were performed in accordance with approved protocols and recommendations for the proper care and use of laboratory animals. Mouse ovarian cancer cell lines, HM-1 (C57BL/6×C3/He F1 origin) and ID8, were used to establish the tumor model in syngeneic mice. ID8 was derived from the mouse ovarian cancer cell line, MOSEC (C57BL/6 origin) and carries the luciferase gene to enable in vivo imaging. The cells were cultured in MEM medium (Gibco-BRL, Gaithersburg, MD, USA) with 10% FBS (Hyclone, Logan, UT, USA), 100 U/ml penicillin (Gibco), and 100 pg/ml streptomycin(Sigma, St Louis, MO, USA) under the condition of humidified atmosphere with 5% C0 2 /95% air at 37°C. Intraperitoneal tumor growth was monitored by in vivo imaging of tumor luminescence (indicating tumor load) by Xenogen IVIS 200 Imaging System.
Development of cisplatin-resistant cell line and cytotoxicity assay
Cisplatin-resistant cell lines (R HM-1) and (R ID8) were produced by culturing the cells with escalating doses of cisplatin (0.1 μg/ml to 2 μg/ml of cisplatin within 2 months, maintained at 2 ȝ g/ml). In vitro cytotoxicity was evaluated by MTT assay in accordance with protocol of the 
Tumor treatment model and depletion of lymphocyte subpopulations
One million R HM-1 cells were inoculated subcutaneously (s.c.) in the left thigh of 
Peritoneal lavage and cytokine assays
The peritoneal cavity of experimental and control R ID8 tumor-bearing mice was lavaged with 
Statistical Analysis
All data expressed as means ± standard error (SE) are representative of at least two different experiments. Comparisons between individual data points were made using a Student's t-test or ANOVA (analysis of variance). Tumor-bearing mice treated by DD regimen received seven cycles (3-day intervals) of paclitaxel (5 mg/kg) and cisplatin (3 mg/kg). Mice treated by MTD regimen received three courses (10-day interval) of higher dosages of paclitaxel (12 mg/kg) and cisplatin (7 mg/kg) by i.p. injection. The control group received PBS. MTD chemotherapy did not significantly reduce the size of R HM-1 tumor, unlike DD chemotherapy (p=0.017, control versus DD) (Fig. 1A) . The R HM-1 tumor was chemosensitive when low dose cisplatin and paclitaxel were administered by DD protocol.
DD efficacy was also better than MTD, even using treatment with single-agent cisplatin or paclitaxel (p=0.0003, DD versus MTD cisplatin) (p=0.002, DD versus MTD paclitaxel) (Supplemental Fig. 1 ). This suggests the therapeutic effect is not dose-dependent and might involve another mechanism that we theorize to be immunological.
Therapeutic effect of DD chemotherapy against platinum-resistant tumor is immunedependent
DD chemotherapy did not produce the same therapeutic effect in immunodeficient tumorbearing mice. (Fig.1B) 
DD chemotherapy preferentially decreased myeloid-derived suppressor cells (MDSCs)
DD chemotherapy significantly reduced the number of myeloid-derived suppressor cells (MDSCs) found in tumor-bearing mice while the same phenomenon was not observed in the control and MTD groups (p<0.0001, DD versus control; P<0.001, DD versus MTD) (Fig. 2B) .
Selective cytotoxicity towards immunosuppressive MDSCs is important for overcoming cancer immune tolerance since MDSCs mediate T cell anergy and promote the development of regulatory T (T reg ) cells that inhibit effective antitumor immune response (10, 11) . Other treatments found to preferentially reduce MDSCs have also documented a corresponding boost in the response of T cells and number of tumor infiltrating lymphocytes (TILs) with associated therapeutic response (12) (13) (14) .
Ideally, cancer treatment should also be able to interfere with T reg function or quantity. The primary function of T reg is to maintain peripheral tolerance by suppressing self-reactive T cells that have escaped the primary lymph node; however, the prevention of autoimmunity also contributes to cancer immune tolerance. (15) In mouse tumor models, the reduction of T reg cells with low dose cyclophosphamide was able to recover the antitumor effects induced by immunotherapy (16) (17) (18) . While the present study did not find DD regimen to be more effective than MTD regimen at reducing the percentage of CD4 + CD25 + T reg cells (P=0.85) (Fig. 2C) , both regimens led to the decline of T reg count (p=0.048, control versus DD) (Fig. 2C) . From this, we believe cisplatin and paclitaxel to have an intrinsic, dose-independent drug effect that is selectively cytotoxic to T reg cells. 
Therapeutic effect of DD chemotherapy is associated with tumor macrophage recruitment DD chemotherapy increased the recruitment of F4/80 + macrophages into the tumor.
Representative flow cytometric data of tumor-bearing mice treated with dose dense regimen showed greater numbers of intratumoral F4/80 + cells than mice treated with MTD regimen (p<0.001, control versus DD, control versus MTD) (Fig. 3A) .
The association of tumor macrophage recruitment with antitumor effect was investigated with the administration of macrophage inhibitor, clodronate liposome. The tumor growth curve showed clodronate liposome partially abolished the antitumor effect of DD chemotherapy whereas the same was not observed in the control group that only received the vehicle (liposome) (p=0.01, clodronate liposome versus liposome only) (Fig. 3B) . We believe the recruitment of macrophages to the tumor is a component of treatment efficacy.
DD chemotherapy promotes tumor-specific CD8 + T lymphocytes responsible for therapeutic effect against platinum-resistant tumor
To delineate the effector cell types responsible for the antitumor effect of a treatment, selective depletion of lymphocyte subpopulations was achieved by injecting monoclonal antibodies against CD8, CD4, or NK1.1 in R HM-1 tumor-bearing mice. Tumor growth curve indicated the antitumor effect of DD regimen was most dependent on CD8 + T cells (p<0.001, anti-CD8 versus rat IgG) (Fig. 4A) , whereas the antitumor effect of MTD regimen did not seem to be associated with any of the monitored immune cells (Fig. 4B) (Fig. 6 ).
Although the sample size was small, the patient results corroborate what we saw in the mouse tumor models and suggest that this treatment warrants further investigation in a larger study. 
ovarian cancer with platinum-resistance. Since we would expect the activation of CD8 + T cells to accompany IFN-γ and IL-2 elevation, we tested and confirmed higher serum levels of these cytokines in 3 of 4 patients whose disease was controlled. While the statistical power of the patient study is challenged by the small sample size, the results are promising enough that the regimen should be investigated in a larger clinical study. We believe that disease control in patients is related to the antitumor immunity that is produced as a consequence of DD treatment.
The results of the present study suggest that antitumor effect of DD regimen is potentiated by tumor-specific immune response, and ergo, is more effective against drug-resistant disease.
Furthermore, the gentler nature of low-dose dose dense regimen makes it ideal for maintenance therapy following the initial marrow-depriving MTD treatment. Of the four patients whose disease was controlled, three had higher serum levels of IFN-Ȗ and IL-2 (red), whereas patients with no response had low or undetectable levels of IFN-Ȗ or IL-2 (black) (DD2 for IFN-Ȗ, **p<0.001, responsive versus unresponsive; DD1 and DD2 for IL-2, **p<0.001 responsive versus unresponsive).
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